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Abstract
Collagen-induced arthritis (CIA) generated in rats or mice has long been a model system for the study of rheumatoid
arthritis in humans. In particular, this system has been used to study the mechanisms and effects of anti-arthritic drugs in the
treatment of the disease. Sodium aurothiomalate (ATM) is an agent often used to treat rheumatoid arthritis in humans;
however, it possesses inherent toxicities which limits its usefulness. Liposome-encapsulated drugs are currently being
developed to minimize the toxicities associated with a variety of potentially beneficial drugs. We have chosen to encapsulate
ATM into small unilamellar vesicles (SUVs) to determine whether greater efficacy would be achieved in treating CIA with
SUV ATM as compared to using the free drug. SUVs were prepared from hydrogenated egg phosphatidylcholine and
cholesterol. These SUVs were very stable. Vesicles stored at 4‡C lost only 0.09% of encapsulated ATM (SUV ATM) after 14
days and were able to reduce collagen-induced arthritis in these mice. Animals treated by i.m. injections of SUV ATM
exhibited a 50% reduction in symptoms. More importantly, histological examination of knee joints of the affected animals
verified that SUV ATM treatment prevented cellular infiltration of lymphocytes into the synovia of the collagen-sensitized
mice. Conditioned media from spleen cell cultures was assayed for the presence of inflammatory lymphokines that might be
affected by SUV ATM to account for the success in suppressing collagen-induced arthritis. ß 1999 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Rheumatoid arthritis (RA), an autoimmune dis-
ease of unknown origin, is associated with in£amma-
tion of the joints and a variety of systemic problems
[1,2]. In addition to joint erosion, it is not uncom-
mon to ¢nd subcutaneous nodules, soft tissue swell-
ing, muscle weakness, vasculitis, or metabolic bone
disorders, such as osteoporosis [1]. In£ammation in
the joints leads to pannus formation, an array of
in¢ltrated lymphocytes, and ¢brin in the joints.
With time, the painful erosion of the cartilage in
the joint takes place. This in£ammatory response is
mediated by the participation of synovial macro-
phages, CD4 and CD8 T-cells [3]. Work by Toyo-
saki suggests that antigens recognized by these in¢l-
trating CD4 T-cells are exclusively on synovial cells
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[4,5]. Moreover, the presence of in£ammatory lym-
phokines such as IL-1, TNF-K, IL-4 as well as TGF-
L1 can be detected immunohistochemically in the
synovium [5^12].
Rheumatoid arthritis has been subject to many
therapies designed to suppress joint pain and in£am-
mation. The failure to identify the etiology of this
autoimmune disorder, makes the rational approach
to e¡ective drug therapy a fairly random process and
less than curative. Anti-in£ammatory drugs tran-
siently reduce symptoms, yet the disease progresses
over time. In addition, non-steroidal anti-in£amma-
tory drugs induce gastric or hepatic toxicity [13]. The
gold salts, among them aurothiomalate (ATM) and
aurano¢n have long been used as anti-arthritic drugs
and do retard the progressive destruction of carti-
lage. They are part of a group of disease-modifying
drugs used to treat RA. Aurothiomalate (ATM) is a
water-soluble thiogold derivative of malic acid and is
used as parenteral drug. Lower doses of ATM (20
mg/month versus 40 mg/month) have also been used
with some positive results [14]. Unfortunately, this
gain in therapeutic e⁄cacy elicited by ATM is ac-
companied by systemic toxicities, such as myelosup-
pression, hepatic toxicity, and dermatitis or stomati-
tis [15]. Patients must then cease this type of therapy.
Other disease-modifying drugs, such as methotrexate
[16,17], su¡er from toxicities associated with anti-
neoplastic drugs, which limits their long-term useful-
ness. These disease-modifying drugs appear to sup-
press the induction of TNF-K and IL-1 [18,19].
The objective here has been to use a well-known
mouse model of rheumatoid arthritis [20,21,37] col-
lagen-induced arthritis (CIA), to evaluate the poten-
tial of liposome-encapsulated aurothiomalate to
more e¡ectively treat rheumatoid arthritis. Immuni-
zation of certain strains of mice and rats with heter-
ologous type II collagen produces a form of rheuma-
toid arthritis that resembles the human form of the
disease [6,11]. The immune response is T-cell depend-
ent. CD4 lymphocytes and IL-2 receptor positive
lymphocytes are soon detected after immunization
[3]. Anti-collagen antibodies can be found in the
sera of susceptible mice. By day 30 after antigen
sensitization, TGF L-2, and the cell surface antigens
Ia, Mac-1, and Gr-1 can be found in the synovium
[22^25]. Several days later, TNF, IL-6, and CD4
cells are detected. These surface markers or cyto-
kine-associated with T-cells tend to increase by day
40 and then level o¡ while macrophage associated
markers remains high.
Liposomes have successfully been used to encap-
sulate toxic drugs and deliver them as a non-toxic
and more e¡ective therapeutic [26^31]. As an exam-
ple, the anti-fungal agent amphotericin B has been
encapsulated into small unilamellar vesicles (SUVs).
This complex is now used to treat deep tissue fungal
infections with signi¢cantly less toxicity than the free
drug. Liposomes with interleukin-2 coupled to the
outer lea£et of SUVs bind to the high a⁄nity form
of the IL-2 receptor and can be used as a targeted
form of a drug delivery vehicle [26]. Liposomes have
been shown to tra⁄c to the synovium of rodents and
humans [32] Clodronate, an anti-arthritic, is being
evaluated in a liposome-encapsulated form to sup-
press CIA in a rat model of arthritis [33]. The bene-
¢cial e¡ects of this liposome-encapsulated drug com-
plex to successfully reduce swelling of the joints may
provide further insight into the cellular mechanisms
of immune suppression and reduction of joint de-
struction.
In the past, the gold drugs have been evaluated in
collagen-sensitized mice and rats with mixed results
[34^36]. Here we present this study which shows that
aurothiomalate encapsulated in SUVs e¡ectively sup-
presses type II collagen-induced rheumatoid arthritis
in DBA/1J male mice and also suppress other sys-
temic e¡ects of the disease. The successful outcome
of the studies using a liposome-encapsulated form of
ATM indicates that e⁄cacy, as an anti-arthritic may
best be achieved when the drug is shielded from the
interstitial tissues prior to delivery to the synovium
or to tissue phagocytes.
2. Materials and methods
2.1. Lipids
Hydrogenated egg phosphatidylcholine was pur-
chased as a dry powder from Avanti Polar Lipids
(Birmingham, AL). Cholesterol, 99%+ was from Sig-
ma. All lipids were stored at 320‡C. Gold sodium
thiomalate was purchased from Pasadena Laborato-
ries (San Clemente, CA) in vials of 50 mg/ml in
water.
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2.2. Mice
Male DBA/1J(H-2q) mice were from Jackson
Laboratories (Bar Harbor, ME) and were used at
6 months of age.
2.3. Preparation and characterization of liposome-
encapsulated aurothiomalate: preparation of
SUV ATM
Gold sodium aurothiomalate (500 mg) was lyophi-
lized to dryness to remove butanol (0.5%) added by
the manufacturer. Immediately before the prepara-
tion of liposomes, the drug was hydrated at 37‡C
in 1.0 ml 0.01 M HEPES (Sigma)^9% sucrose, pH
7.4 at 37‡C. Small unilamellar liposomes were pre-
pared using HEPC and cholesterol at a molar ratio
of 2:1. 40 mg of total lipid were dissolved in 2 ml of
chloroform/MeOH (2:1, v/v) and evaporated to dry-
ness under nitrogen at V42‡C. The lipid ¢lm was
then further dried under vacuum overnight to re-
move all traces of chloroform.
The lipid ¢lm was hydrated by incubation in 1 ml
of HEPES-sucrose at 56‡C for 10 min with occasion-
al mixing. The solubilized ATM was then added and
the mixture incubated for 5 min. Small unilamellar
liposomes were made by sonication using a probe
sonicator (50 mHz, Branson Soni¢er) at room tem-
perature for 10 min. Drug containing SUVs re-
mained in the supernatant after centrifugation. The
SUVs were further incubated at 56‡C for 10 min,
centrifuged at 14 000Ug, 2 min. Non-encapsulated
ATM was removed by chromatography over Sepha-
dex G50-80 in the same bu¡er. Liposome-encapsu-
lated ATM was stored under nitrogen at 4‡C.
2.4. Encapsulated drug concentration
The concentration of ATM was determined by
plasma emission spectroscopy (Quest Laboratories,
Fort Collins, CO). The phospholipid concentration
in SUV preparations was approximately 5 mg/ml
total lipid.
2.5. Determination of vesicle stability
The integrity of the phospholipids monitored by
thin layer chromatography. Aliquots of SUV ATM
were applied to Silica Gel (Whatman) thin layer
plates and chromatographed in CHCl3/MeOH (7:3)
along with puri¢ed lipid standards. The plates were
developed by spraying with 50% (v/v) H2SO4 and
heating. The retention of the encapsulated ATM
was determined by ¢ltration. The liposome-encapsu-
lated drug was stored under nitrogen at 4‡C. At var-
ious times after storage, aliquots of SUV ATM were
diluted into HEPES-sucrose bu¡er and centrifuged at
2900 rpm in Centricon 30 ¢lter units for 60 min, 4‡C.
The gold concentration of the ¢ltrates was deter-
mined as described for SUVs and corrected for dilu-
tion.
2.6. Determination of vesicle diameter
Samples of SUV ATM were diluted with 2% phos-
photungstic acid and examined by electron micros-
copy at 55 000U magni¢cation. The diameter of
the vesicles was measured using a scale of 18.1 nm/
mm.
3. Induction of collagen-induced arthritis and
treatment with liposomal ATM
Male DBA/1 mice were injected intradermally at
the base of the tail with 100 Wg of chick Type II
collagen (Sigma)in 0.1 N HOAc. which had been
emulsi¢ed in complete Freund’s adjuvant (Sigma)
All mice were boosted with 100 Wg of collagen emul-
si¢ed in incomplete Freund’s adjuvant (Sigma) on
day 21 after the initial sensitization. Mice were
treated with SUV ATM or ATM in HEPES-sucrose
by injection in one quadracep muscle (i.m.). Subse-
quent injections were given to alternating quadracep
muscles. Treatments were initiated on day 1 at the
same time as the initial antigen challenge. Mice were
treated once per week thereafter. Mice were bled
intermittently to assess anti-collagen antibody pro-
duction. At the completion of the studies, animals
were killed and splenocytes isolated and subcultured
for subsequent in vitro studies.
3.1. Arthritic index
All groups of mice were observed weekly for signs
of redness and swelling in the fore and hind paws.
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The same individual always observed the mice while
two other scientists not involved with the study
[32,59^61] veri¢ed the symptoms of CIA. It was ob-
served those collagen-sensitized animals would occa-
sionally have red and swollen eyelids in addition to
severely swollen feet. The criteria for ranking the
development and extent of arthritis were as follows:
each foot of an animal was either normal (score = 0),
or red (+1). The degree of swelling was ranked as
mild (+1), moderate (+2), or severe (+3). The devel-
opment of arthritis followed a characteristic pattern
of redness followed by progressive swelling, which
was easily distinguished. Each foot had a maximal
score of (+4). If an animal had an in£amed eye it
received an additional (+1). The maximum score
possible was 4U4 (feet)+2 (eyes) = 18. The arthritic
index was = (x/18)U100. The data from all treatment
groups were analyzed using ANOVA and Tukey^
Kramer HSD statistical methods to evaluate en-
capsulated drug reduction of collagen-induced arthri-
tis.
3.2. Histological examination
At the end of a study, the hind legs and feet of
mice from each treatment group were removed and
quick-frozen in HistoPrep (Fischer Scienti¢c). Sam-
ples were stored at 380‡C until sectioning and stain-
ing in Hematoxylin^Eosin. Slides were examined and
photographed at 40U magni¢cation.
3.3. Anti-collagen EIA
Immulon EIA plates were coated with chick type
II collagen (1 Wg/ml) in 0.01 M sodium carbonate,
pH 8.2, 4‡C, overnight. Plates were washed with
phosphate-bu¡ered saline, pH 7.4^0.2% Tween 20,
and blocked for 60 min with 3% ovalbumin/PBS.
Plates were washed with PBS-Tween, and incubated
with dilutions of antisera for 60^120 min, 37‡C.
Plates were again washed, and incubated with goat-
anti-mouse IgG conjugated to alkaline phosphatase
(Southern Biotechnology) at a dilution of 1:300. Col-
or development was initiated by the addition of p-
nitrophenylphosphate (Sigma), 1 mg/ml in diethanol-
amine bu¡er, pH 8.6. Absorbance was read at
450 nm.
4. Results
4.1. Preparation and characterization of SUV ATM
Sodium aurothiomalate was easily encapsulated
into SUVs and the protocol was extremely reprodu-
cible. These SUVs were quite stable during storage at
4‡C with little leakage of aurothiomalate. This is
shown in Fig. 1. Only 0.09% of the encapsulated
drug leaked out during a 7-day period. Thin layer
chromatography was used to monitor any gross
changes in the oxidation state of the lipids. No major
changes in the oxidation of hydrogenated egg phos-
phatidylcholine or cholesterol were found, although
this is not a sensitive indicator of lipid oxidation.
Preparations of SUV ATM were negatively stained
with 2% phosphotungstic acid and observed by elec-
tron microscopy (Fig. 2). The average diameter was
approximately 72.4 nm when SUVs were measured
with this method (Fig. 2).
4.2. Development of CIA
The animal model of rheumatoid arthritis was es-
tablished as described [20,21,36^38] and the observa-
Fig. 1. Aliquots of SUV ATM were incubated at 4‡C for the
indicated intervals. A 50-Wl amount of liposomes was added to
1.5 ml of HEPES-sucrose bu¡er and centrifuged at 2900 rpm,
4‡C for 60 min. The ¢ltrates from centrifugation were analyzed
for the concentration of ATM as described.
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tions of the symptoms were con¢rmed by three indi-
viduals. Redness of the fore paws and hind paws was
detectable by day 8. All animals sensitized with chick
collagen mounted an immune response and anti-col-
lagen antibodies were detectable in the sera by day
32. The symptoms of collagen-induced arthritis con-
sisted initially of red and then swollen hind feet by
days 21^28. The disease then progressed to the front
feet. Over time, the mice became less active. In addi-
tion, we observed that collagen-sensitized animals
(without any drug treatment) occasionally had one
or two red and swollen eyes, which varied in intensity
and frequency of this reaction. All mice were boosted
on day 21 with collagen and the studies were allowed
to proceed for 70^80 days.
4.3. Treatment of collagen-sensitized mice with ATM
or SUV ATM
The mice receiving either form of the drug were
¢rst injected on the same day that they ¢rst received
collagen. This was done to see if ATM or SUV ATM
inhibited the activation phase of antigen sensitiza-
tion. Several pilot studies were carried out using
small numbers of animals (¢ve mice per treatment
group) to determine if liposomal therapy would alter
the development of arthritis. We observed that treat-
ment with SUV ATM de¢nitely suppressed the mag-
nitude of arthritis in male DBA/1 mice. As compared
to the collagen-treated mice (no drug treatment), the
appearance of the hind feet as well as the fore paws
of these mice receiving SUV ATM resumed a normal
appearance and the foot pads were not swollen.
Moreover, there was little residual redness. Two
large-scale studies (12 mice per treatment group)
were then carried out to follow this e¡ect once it
was seen that a distinct result was achieved with
SUV ATM.
4.4. Escalating dose study
A range of liposome encapsulated drug concentra-
tions was ¢rst chosen to determine how arthritic mice
would respond to treatment and over what time pe-
riod the symptoms of CIA would be altered. Fig. 3
presents the results of an 81-day study. The animals
were both sensitized to collagen and treated on day
1. The concentration of drug per animal ranged from
Fig. 2. A preparation of SUV ATM was stained with 2% phos-
photungstic acid, and visualized by electron microscopy at
55 000U. The diameter of the vesicles was determined by com-
parison to the factor of 18.1 nm/mm.
Fig. 3. The arthritic index from an escalating dose study of
SUV ATM or ATM treatment of collagen-sensitized DBA/1
mice. Collagen (open circles), untreated mice (normals, (hatched
squares), collagen+ATM treated (diamonds), collagen+ATM+
SUV (triangles) and collagen+SUV ATM (open squares)
present increased foot swelling during 81 days. The drug con-
centration ranged from 4 to 16 mg/kg per animal.
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4 to 20 mg/kg (Fig. 4) over the duration of the ex-
periment. There were ¢ve treatment groups consist-
ing of untreated or normals, collagen-treated, colla-
gen+ATM-treated, collagen+ATM+empty SUV-
treated, and collagen+SUV ATM-treated. The last
treatment group was included to compare the indi-
vidual components of the encapsulated drug system.
As seen in Fig. 3, by day 75, the arthritic index of
animals sensitized with collagen alone was almost
60% and all animals exhibited symptoms. Treatment
of collagen-sensitized mice with ATM or empty
SUV+ATM did not result in reduction of arthritic
symptoms. Treatment of mice with collagen and
SUV ATM reduced foot swelling. The arthritic index
in SUV ATM-treated mice was 20% by day 75. The
reduction in symptoms was evident by day 40 and
remained at the same level for the duration of the
study. Statistical analysis (ANOVA) of these studies
on day 82 (Fig. 6) indicated that a comparison of
collagen treatment versus collagen+SUV ATM dem-
onstrated a P-value of 0.0004. Statistical analysis us-
ing the Tukey^Kramer HSD compares the di¡erence
of the means of each treatment group. The more
positive the value, the more signi¢cant the compar-
ison. Comparing the value between the SUV ATM
treatment group to either the collagen or the colla-
gen+ATM group gave a value 0.116516, which is
signi¢cant. In contrast, comparing the collagen treat-
ment group to collagen+ATM group gave a value of
Fig. 4. The drug dose of SUV ATM or ATM during the study
presented in Fig. 3 is shown in mg/kg of total body weight
based on the weight of a 22-g mouse. Fig. 6. A The comparison of symptoms among the treatment
groups on day 81 from the study presented in Fig. 5.
Fig. 5. The arthritic index of a elevated drug dose study. Colla-
gen-sensitized mice were treated with 104 mg/kg for 81 days.
Treatment groups were collagen-sensitized (¢lled squares), colla-
gen+ATM (¢lled diamonds), collagen+SUV ATM (¢lled
circles), and normals (¢lled triangles).
BBAMEM 77670 1-9-99
P.J. Konigsberg et al. / Biochimica et Biophysica Acta 1421 (1999) 149^162154
0.066516. and a value of 0.024081 when compared to
collagen+ATM+SUV group. Negative values arising
from such a comparison are not signi¢cant. In this
study group, treatment of collagen-sensitized mice
with the 20 mg/kg of non-encapsulated drug
(ATM) was without e¡ect as any reduction of ar-
thritic symptoms occurred.
4.5. Elevated dose study
This study consisted of four treatment groups:
normals or untreated controls; collagen-treated; col-
lagen+ATM-treated; and collagen+SUV ATM-
treated. Animals were treated with 104 mg/kg of
drug. As seen in Fig. 5, SUV ATM also reduced
the magnitude of the arthritic index even when
used at a 5-fold greater concentration than used in
the previous study. The reduction in symptoms was
already evident by day 29. The arthritic index of the
mice treated with SUV ATM did increase somewhat
during the course of the study, yet this group always
exhibited far fewer symptoms over all. The data from
day 80 (Fig. 6) were analyzed by ANOVA and the P-
value comparing the statistical signi¢cance between
the group treated with SUV ATM and the other
treatment groups was 6 0.0001. There is little di¡er-
ence between the collagen treatment group and the
collagen+ATM group. The Tukey^Kramer HSD val-
ue for signi¢cance was 0.247077 when the collagen
group was compared to the collagen+SUV ATM
group. When the collagen group was compared to
the collagen+ATM group, a value of 0.102723 was
obtained. The free drug suppressed symptoms only
at the higher concentration, but was never as e¡ec-
tive as the encapsulated drug in this regard.
None of the animals showed any overt signs of
drug toxicity. All animals maintained the same
weight from group to group. Those receiving SUVs
had a slight weight gain that was not statistically
signi¢cant. The mean weight of the mice at the end
of the studies was 20^21 g. Reduction in activity was
observed in all collagen-treated animals, but no loss
of agility was observed in the arthritic mice. All mice
were always able to readily retrieve food and water.
Most importantly, the SUV ATM-treated mice were
as active as control mice that had never been colla-
gen-treated.
4.6. Histological examination of knee joints
The e¡ect of drug therapy on cellular ¢ltration
into the joints of arthritic mice was assessed by mi-
croscopic examination of the knee joints. Mice from
the dose escalation study where the drug dose varied
from 4 to 20 mg/kg were killed on day 81. The hind
legs and spleens were removed and the legs were
quick-frozen and stored at 380‡C. Examination of
multiple slides from each of the treatment groups
provided good documentation of the e¡ect of drug
therapy on cellular in¢ltration. Collagen-sensitized
mice receiving no drug therapy had a signi¢cant de-
gree of cellular in¢ltration into the synovium (Fig.
7A). A large zone of cells is present in the area below
the synovial membrane (SM, Fig. 7A). Examination
of the sectioned and stained joints revealed that col-
lagen-sensitized mice treated with varying doses of
SUV ATM (Fig. 7B) had minimal cellular in¢ltra-
tion. Samples from these mice were similar to the
control or ‘normal’ mice, which had no collagen or
drug therapy (Fig. 7C). The presence of osteoclasts
can be seen in the bony end plate of the sample
presented in Fig. 7C. The free drug (ATM) combined
with empty SUVs was not therapeutic as demon-
strated by the presence of cellular in¢ltration in the
joint and no or little reduction in foot swelling (data
not shown). It is clearly evident that those mice
treated with SUV ATM had almost no lymphocytic
in¢ltration in the synovium as compared to collagen-
sensitized animals.
4.7. Immunological characterization of SUV
ATM-treated mice
Obvious morphological changes in arthritic ani-
mals accompanied the treatment with SUV ATM
and there was a noticeable reduction in both the
swelling of the front and hind feet and in£ammation
of the eyes. Attempts were made to identify the tar-
get cell or biochemical pathway that was altered by
SUV ATM. We chose to sample peripheral blood for
anti-collagen antibodies. In addition, during the
course of a study several animals of each group
were killed on days 32 and 81 in order to isolate
and sub-culture splenocytes in the presence of exog-
enous collagen to follow the production of cytokines
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Fig. 7. (A^C) Histological sections of knee joints from collagen-treated and non-treated mice: (A) type II chick collagen treatment;
(B) treatment with SUV ATM; and (C) normals or no collagen. Frozen knee joints were sectioned and stained with Hematoxylin^Eo-
sin. JC is the synovial joint cavity, SM indicates the synovial membrane and AC locates the articular cartilage seen in C in non-colla-
gen sensitized animals. 38U. Note the enhanced thickness of the synovial membrane in A.
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in the periphery in response to SUV ATM therapy in
vivo.
The appearance of anti-chick collagen antibodies
in the sera of the mice was followed by an ELISA for
anti-collagen IgG. All mice sensitized to chick colla-
gen had produced these antibodies. There was a very
slight reduction of antibody production by drug ther-
apy using SUV ATM (Fig. 8). The levels of anti-
collagen antibodies remained elevated throughout
the duration of the study in all groups of collagen-
sensitized animals.
To assess lymphokine production in response to
therapy, splenocytes were cultured in the presence
of 10 Wg/ml of chick collagen for 5^7 days. Aliquots
of the conditioned medium from these cultures were
assayed for the presence of IL-1L, IL-2, I-4, TNF,
Q-IFN, TGF-L1, transferrin, and IL-10 using either
bioassays (IL-2, TNF) or ELISAs (IL1-L, IL-4,
Q-IFN, TGF-L1, transferrin, [41,42]. There was a
slight reduction in the level of IL-4 when collagen-
sensitized mice were treated with SUV ATM. There
was no single cytokine in this group including IL-2
whose production was signi¢cantly a¡ected by SUV
ATM. All the other cytokines or acute phase pro-
teins monitored were present and detectable, but
were not signi¢cantly a¡ected, positively, or nega-
tively, by SUV ATM [19,24].
Lymphocytes were isolated from peripheral blood
Fig. 7 (continued).
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and stained for CD4, CD8 or the macrophage sur-
face antigens F480 and MAC-1 to see if major
changes could be detected in peripheral blood lym-
phocytes of treated versus non-treated CIA mice [3^
6,22]. No major changes in these surface antigens
were found. The ratio of CD4 :CD8 cells was
V2.5:1 consistent with the normal in vivo composi-
tion of these T-cell subsets. No altered distribution of
macrophages in the peripheral blood was found evi-
denced by F480 or MAC-1 staining.
5. Discussion
Sodium aurothiomalate was easily encapsulated
into stable small, unilamellar vesicles (SUVs) and
this material was therapeutically e¡ective. SUV
ATM suppressed collagen-induced arthritis (CIA)
in male DBA/1J mice (Figs. 3^5). The macroscopic
signs of arthritis as well as cellular in¢ltration into
the joints was signi¢cantly reduced by intramuscular
injections of SUV ATM over an 81-day treatment
period compared to non-treated animals having
CIA. Suppression of arthritis was observed in both
studies showing a broad range of the e¡ective encap-
sulated drug dose. A 50% reduction in the symptoms
was achieved at 16 mg/kg after 81 days. Increasing
the injectable dose to 104 mg/kg did give a more
de¢ned pattern of suppression, but the higher dose
produced a slight suppression in the presence of the
free drug that was not observed in the ¢rst study
(Figs. 3 and 5). The free-drug was only slightly ef-
fective in suppressing CIA at the higher concentra-
tion of 104 mg/kg. It is clear in this liposomal system
that greater e⁄cacy occurs using liposome-encapsu-
lated drug than would be the case using ATM alone.
This is a hallmark of successfully encapsulated drugs.
We observed a reduction in the local concentration
of in¢ltrating lymphocytes present in the joint of the
hind limbs when mice are treated with SUV ATM,
but not with the free drug (Fig. 7A^C). The appear-
ance of tissue samples from SUV ATM-treated mice
was very similar to those of mice that had not re-
ceived collagen injections. Moreover, the absence of
cellular in¢ltration is directly correlated with a de-
crease in foot swelling and in a few of the animals
there was a reduction in eye swelling. It has been
observed that a reduction of macrophages in the
perivascular space of the synovium is observed in
samples of needle biopsies from ATM-treated pa-
tients who have had active rheumatoid arthritis [40].
We examined the capacity of lymphoid organs in
the periphery modulate changes in the ability of res-
ident T- and B-cells to produce in£ammatory lym-
phokines. It was of interest to see if collagen-sensi-
tized mice treated with SUV ATM would produce
less IL-1L or TNF-K among others. We could not
detect the presence of in£ammatory lymphokines at
concentrations above background. We assayed both
sera and conditioned medium for TNF, transferrin,
TGF-L1, IL-1, IL-2, IL-4 and IL-10.
An obvious cellular target for SUV ATM would
be tissue and synovial macrophages [43^48]. Phago-
cytosis of SUV ATM would then lead to an altera-
tion in the in£ammatory cytokine pro¢les. Moreover,
intact SUV ATM carried by the circulation can
easily reach the synovium [32]. The average diameter
of SUV ATM is V72 nm. It has been reported that
liposomes 80^90 nm in diameter injected subcutane-
ously could be found in the blood 12^24 h postin-
jection [42]. Although SUV ATM is injected intra-
Fig. 8. The presence of anti-chick collagen antibodies in the
sera of arthritic mice was detected by an ELISA using alkaline
phosphatase-conjugated anti-mouse IgG1 antibodies (Southern
Biotechnology). Mice were bled on day 32 after sensitization
while being treated at an ATM dose of 104 mg/kg.
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muscularly, it probably does not remain at the site of
injection and in time, some could enter the synovium
[32]. Biodistribution studies were not carried out to
determine the concentration of the drug in the major
organs and tissues among the treatment groups.
Within the synovium of humans with rheumatoid
arthritis or mice with CIA there is a signi¢cant in¢l-
tration of lymphocytes (Figs. 3^5). The presence of
both CD4 and CD8 T-cells, macrophages and B-
cells in the synovium has been well-documented
[39,40]. By day 30 after antigen sensitization, the
lymphokine TGFL-2 and surface molecules Iaq,
Mac-1, and Gr-1 can be found on cells that have
in¢ltrated the synovium. Several days later, the lym-
phokines TNF, IL-6, and CD4 cells are detected.
These surface markers or cytokine-associated with T-
cells tend to increase by day 40 and then level o¡
while macrophage associated markers Mac-1, Gr-1
remain high [39^41]. The identity of the autoantigen,
which elicits the cycle of in£ammatory processes in
rheumatoid arthritis in humans, is unknown. Immu-
noreactive cells are present and active in the synovi-
um even if the antigen is a self-antigen and elicits a
MHC class I response [48] or whether a foreign anti-
gen, such as collagen, Mycobacteria, or Borellia, is
present leading to a MHC class II response.
At the present time, the understanding of ATM
e⁄cacy or toxicity is hindered by the identi¢cation
of a de¢ned biochemical or cellular target a¡ected by
the drug. Several cell types and many di¡erent bio-
chemical systems appear to be altered by the gold
drugs. The various systems a¡ected by gold drugs
include complement activation [49], collagenase se-
cretion [50^52], macrophage and neutrophil activa-
tion [18,49,53], and inhibition of neutrophil chemo-
taxis [54], inhibition of lymphocyte proliferation and
immunoglobin synthesis [54^58].
Interestingly, the gold drugs aurothiomalate and
aurano¢n do not suppress collagen-induced arthritis
in rodents in a consistent manner. Yet, use of lipo-
some-encapsulated sodium aurothiomalate consis-
tently reduced the symptoms associated with colla-
gen-induced arthritis. Some investigators report that
ATM does not suppress collagen-induced arthritis
[59,60]. Others report that only aurano¢n exerts im-
munosuppressive e¡ects in a rat model and does not
work in a mouse model [61] Aurothiomalate seems to
cause some toxicity among strains of mice [59^61].
Aurano¢n appears somewhat ine¡ective in reducing
symptoms of arthritis in collagen-treated rats [59^
61]. Aurothiomalate can suppress in£ammatory re-
sponses elicited by carragenen in the footpad or the
cheek pouch of the mouse [62]. A long-term treat-
ment of three mouse strains with gold drugs was
carried out to follow changes in pharmacokinetic
pro¢les of the drug even though the mice are not
sensitive to the drug [62].
Oddly enough, using murine lymphocytes, both
aurothiomalate and aurano¢n can be studied in vitro
and a¡ect a variety of biochemical and immunolog-
ical parameters. Suppression of lymphocyte prolifer-
ation, protein kinase C activity, glucocortico receptor
activity and NF UB activity occur [18]. Again, these
studies were performed using non-encapsulated drugs
where charge e¡ects may play a role in intracellular
entry and a rodent’s ability to respond to the drug.
It should be pointed out that in this liposomal
system of drug delivery, e⁄cacy was achieved at en-
capsulated drug concentrations where the free drug
was ine¡ective.
We did not observe any overt signs of drug tox-
icity during the course of the work. All study groups
including the negative control group maintained their
weight (V20^21 g). The collagen-treated mice exhib-
ited a reduced level of activity relative to the negative
controls as their feet became progressively swollen,
but no other changes were observed. Collagen-
treated mice that received SUV ATM were as active
as non-collagen-treated ones. Irrespective of the
speci¢ed cellular or biochemical target, encapsulation
of ATM within the internal aqueous space of small
unilamellar vesicles strongly enhances its e⁄cacy in
reducing the overt symptoms of type II collagen-in-
duced arthritis reduced, shown by reduced foot swell-
ing and a virtually no cellular in¢ltrate in the syno-
vium. The study also suggests that the variability in
the sensitivity of rodents to a drug such as ATM may
re£ect the fact that this derivative of malic acid does
not easily cross the cell membrane. Obviously, encap-
sulation shields the cell from a charged molecule.
Sodium aurothiomalate, aurano¢n, and sulfasalazine
are part of a small number of anti-arthritic drugs
having the capacity to retard the progression of rheu-
matoid arthritis at the cost of frequent drug toxicity.
This work has shown that e⁄cacy may be reduced by
delivery into the cell when encapsulated.
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